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Abstract
Background: Inability to perform defibrillation threshold (DFT) testing during implantable
cardioverter defibrillator (ICD) implantation due to co-morbidities may influence long-term
survival.
Methods: Retrospective review at The University of Michigan (1999–2004) identified
55 patients undergoing ICD implantation without DFT testing (“No-DFT group”). A randomly
selected sample of patients (n = 57) undergoing standard DFT testing (“DFT group”) was
compared in terms of appropriate shocks, clinical shock efficacy and all-cause mortality.
Results: DFT testing was withheld due to hypotension, atrial fibrillation with inability to
exclude left atrial thrombus, left ventricular thrombus, CHF and/or ischemia. The No-DFT
group had a similar appropriate shock rate, but lower total survival (69.1% vs. 91.2%,
p = 0.004) than the DFT group. The No-DFT group had a higher incidence of ventricular
fibrillation (VF) episodes (9.1% vs. 3.1%, p = 0.037), and deaths attributable to VF (3 of 17
deaths vs. 0 of 5 deaths) compared to the DFT group. Multivariate analysis found a trend
toward increased risk of death in the No-DFT group (HR 3.18, 95% CI 0.82–12.41, p = 0.095)
after adjusting for baseline differences in gender distribution, NYHA class and prior CABG.
Conclusions: In summary, overall mortality was higher in the No-DFT group. More deaths
attributable to VF occurred in the No-DFT group. Thus, DFT testing should therefore remain
the standard of care. Nevertheless, ICD therapy should not be withheld in patients who meet
appropriate implant criteria simply on the basis of clinical scenarios that preclude routine
DFT testing. (Cardiol J 2007; 14: 463–469)
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(ICDs) are the most effective treatment for those
patients who are at high risk for life threatening
ventricular arrhythmias. Randomized clinical trials
have clearly shown that ICDs are superior to an-
tiarrhythmic drug therapy in survivors of cardiac
arrest, and that ICDs provide an additional mortal-
ity reduction in both patients with ischemic and non-
ischemic cardiomyopathy beyond that provided by
optimal medical therapy alone [1–8]. With a stead-
ily increasing elderly population [9] and Medicare
databases suggesting an underutilization of ICD
therapy [10], it is likely that the number of implants
will increase exponentially in coming years. It is
believed to be important that defibrillation thresh-
old testing (DFT) is performed at the time of ICD
implant to confirm a sufficient programmed shock
strength [11–13]. Earlier ICD systems frequently
required that the location, type or number of elec-
trodes be altered in order to ensure an adequate
defibrillation safety margin. Due to advances in lead
technology the requirement for ICD system modi-
fications is less frequent and a defibrillation safety
margin of 10 J is usually easily established [14].
Defibrillation threshold testing at the time of
ICD implant is currently the standard of care. How-
ever, there are clinical situations where induction
of ventricular fibrillation (VF) may be associated
with negative outcomes. This would include signif-
icant hypotension, respiratory distress, acute con-
gestive heart failure, known large ischemic burden
and left atrial thrombus in the setting of atrial fi-
brillation. When implant DFT testing is not per-
formed, programmed shock strength is usually set
to maximal output. There is very little published
data to our knowledge that describes the clinical
outcomes in patients who do not undergo routine
DFT testing at the time of ICD implantation.
The aim this study is to compare the outcomes
of patients who did not undergo DFT versus those
who did undergo DFT testing at implant.
Methods
A retrospective chart review was done to iden-
tify all patients who underwent ICD implantation
without DFT testing at the University of Michigan
between 1999 and 2004. We identified patients who
did not undergo DFT testing at the time of implan-
tation over this time period as the “No-DFT group”.
Patients who underwent DFT testing at implanta-
tion during the same time period were randomly
identified as the DFT group. Primary outcome var-
iables included appropriate shocks, clinical shock
efficacy and all-cause mortality. Data on demograph-
ic variables, underlying cardiac disease, use of med-
ications and reason for not testing were collected.
Data on total number of shocks and appropriate
therapies was also collected. Clinical Shock Effica-
cy was defined as shocks effective in terminating
ventricular tachycardia or fibrillation.
Method of DFT testing and programmed
shock energy in DFT group
In the DFT group, a step-down DFT testing
protocol was used. VF was induced by T-wave
shocks. In those patients in whom VF could not be
induced by T-wave shock, direct current induction
was performed. The vast majority of patients re-
ceived an initial defibrillation test shock of 21 joules.
If this shock was successful, VF was again induced
and subsequent defibrillation shocks were given at
17, 14 and then 11 joules with a 5 minute waiting
period between inductions. First shock energy was
programmed 10 joules higher than the lowest suc-
cessful defibrillation test shock.
Statistical analysis
Statistical analyses were performed using the
Statistical Program for Social Sciences (version 13.0
SPSS Inc., Chicago, Illinois). Frequency analysis
was done to identify the distribution of variables.
An independent sample t-test was used to detect
differences between continuous variables. Contin-
uous variables are represented as the mean ±
± standard deviation. Chi-square test was used to
test association between categorical variables.
A Fisher’s exact test was used when appropriate.
A p value of < 0.05 was considered to be statisti-
cally significant. The probability of survival was es-
timated and graphically displayed according to the
method of Kaplan and Meier, with comparison of
cumulative events by the log-rank test. Cox pro-
portional hazards regression was used to develop
multivariate regression models for the endpoint of
survival. It was found that the DFT covariate in-
teracted with follow-up time and so the DFT cov-
ariate was dichotomized at 1.5 years. Based on uni-
variate analyses and clinical correlation, the vari-
ables (gender, prior CABG, NYHA class, No-DFT
testing) were included in the regression model.
Due to limited data available, anti-arrhythmic use
was not included in the model. Kaplan-Meier and
Cox regression analyses were performed using
SAS software version 9.1.3 (SAS Institute Inc,
Cary, NC).
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Results
Table 1 compares the baseline characteristics
in the No-DFT and DFT groups. The mean age of
the No-DFT group (n = 55) was slightly higher than
that of the DFT group (n = 57) (64 ± 12 years vs.
58 ± 13 years, p = 0.06). The distribution of gen-
der was similar between the No-DFT group and the
DFT group (27.8% women vs. 15.8% women,
p = 0.125). Patients in the No-DFT group were fol-
lowed for a mean of 540 ± 521 days vs. 525 ± 377
days for the DFT group (p = 0.865). Although the
prevalence of CAD was similar between the DFT
group and the No-DFT group (68.4% vs. 70.9%,
p = 0.775), a higher percentage of the No-DFT
group had a history of congestive heart failure
(78.4% of No-DFT group vs. 47.1% of DFT group,
p = 0.001). The mean ejection fraction was higher
in the DFT group compared to the No-DFT group
(25 ± 11 vs. 20 ± 12, p = 0.076). Significantly more
patients in the No-DFT group had prior CABG as com-
pared to the DFT group (42.6% vs. 24.6%, p = 0.044).
The distribution of medications such as ACE inhib-
itors (p = 0.84) and beta blockers (p = 0.51) were
not significantly different between the No-DFT and
the DFT groups. The use of digoxin and amiodar-
one were both higher in the No-DFT group as com-
pared to the DFT group and these differences were
statistically significant (p = 0.001). The indications
for ICD implantation are also listed in Table 1.
The characteristics of the implanted devices
including manufacturers, system type, pacing
threshold, sensing and lead impedance are listed in
Table 2. The most common reasons for not perform-
ing DFT testing at the time of implant were hypo-
tension (34.5%), AF and inability to exclude left
atrial thrombus (27.3%), left ventricular thrombus
(5.5%), CHF (7.3%), ischemia (7.3%), and others
as listed in Table 3. There were no patients in the
DFT group who did not have at least a 10 joule safe-
ty margin between lowest successful defibrillation
test shock and programmed first shock energy.
The total number of shocks (51 in No-DFT group
vs. 54 in DFT group, p = 0.57) and total appropriate
treatments (46 vs. 48, p = 0.19) did not differ between
the two groups. Of the 51 shocks in the study popula-
tion, 91.7% were appropriate therapies as compared
to 94.1% appropriate therapies in the DFT group
(p = 0.99). All appropriate therapies did result in ter-
mination of the underlying ventricular tachyarrhyth-
mia. Of the patients who did not undergo DFT test-
ing, 69.1% were alive during follow up as compared
to 91.2 % in the DFT group (p = 0.004). There was
a higher percentage of patients with episodes of ven-
tricular fibrillation in the No-DFT group as compared
to the DFT group (9.1% vs. 3.1%, p = 0.037) (Table 4).
Table 1. Distribution of variables between patients who underwent defibrillation threshold (DFT) testing
vs. those who did not at the time of ICD implantation.
Variables No-DFT group (n = 55) DFT group (n = 57) P
Mean age (years) 64.1 ± 12.1 58.8 ± 13.9 0.06*
Female 15 (27.8%) 9 (15.8%) 0.167^
Coronary artery disease 39 (70.9%) 39 (68.4%) 0.775#
Prior coronary artery bypass grafting 23 (42.6%) 14 (24.6%) 0.044#
NYHA class III + IV 40 (78.4%) 24 (47.1%) 0.001#
Duration of follow up 540.16 ± 521.6 525.58 ± 377.11 0.865*
ACE inhibitor 41 (77.4%) 45 (78.9%) 0.84#
Beta blocker 36 (67.9%) 42 (73.7%) 0.51#
Digoxin 39 (75%) 23 (40.4%) 0.001#
Amiodarone 16 (69.6%) 13(22.8%) 0.001#
Ejection fraction 20.98 ± 12.48 25.12 ± 11.33 0.076*
ICD indications 0.332#
Ventricular tachycardia 10 (18.2%) 12 (21.1%)
Ventricular fibrillation 6 (10.9%) 4 (7.0%)
NSVT¶ 17 (30.9%) 24 (42.1%)
Low ejection fraction¶ 11 (20%) 7 (12.3%)
MADIT II 8 (14.5%) 10 (17.5%)
Infiltrative 1 (1.8%) 0
Not documented 2 (3.6%) 0
*p based on t-test, #p based on c2, ^Fischer exact test, ¶plus inducible sustained ventricular tachycardia/syncope
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Cause specific mortality data was available in
19/22 (86.3%) patients (Table 5). Kaplan Meier sur-
vival curves are represented in Figure 1. A signifi-
cant survival benefit was noted in patients who
underwent DFT testing compared to the No-DFT
group (p = 0.028). Cox regression analysis showed
that the No-DFT group had a significantly higher
hazard ratio to predict mortality before adjusting for
other factors (HR 4.59, 95% CI 1.3–16.28, p = 0.018).
The final regression model after adding other vari-
ables showed several independent predictors of
mortality including No-DFT testing (HR 3.18, 95%
CI 0.82–12.41, p = 0.095) and NYHA (HR 2.59, 95%
CI 0.79–8.45, p = 0.115). Male gender (HR 0.47,
95% CI 0.18–1.27, p = 0.136) and history of prior
CABG (HR 0.64, 95% CI 0.21–1.96, p = 0.43) ap-
peared to be protective (Table 6). There were more
deaths attributable to VF in the No-DFT group
(3 of 17 deaths, 17.6%) as compared to the DFT
group in which no deaths from VF were recorded.
Table 2. Characteristics of device implants.
No-DFT group (n = 55) DFT group (n = 57) P
Device manufacturers < 0.001#
Guidant 34 (60.7%) 46 (80.7%)
Medtronic 14 (25%) 9 (15.8%)
Ventak 7 (12.5%) 0
Unknown 1 (1.8%) 2 (3.5%)
System type < 0.001#
Single 24 (42.9%) 46 (80.7%)
Dual 24 (42.9%) 8 (14.0%)
Unknown 8 (14.3%) 3 (5.3%)
Pacing threshold 0.91 ± 0.66 0.77 ± 0.58 0.236*
Pace Impedance 679.8 ± 230.8 832.6 ± 335.2 0.007*
R wave amplitude [mV] 12.08 ± 6.3 12.84 ± 6.2 0.549*
*p based on t-test, #p based on c2; DFT — defibrillation threshold
Table 3. Comorbid conditions responsible for
not performing defibrillation threshold (DFT)
testing at the time of ICD implantation in the
No-DFT group.
Comorbid conditions Number (percent)
Hypotension 19 (34.5%)
Atrial fibrillation with 15 (27.3%)
no pre-procedure TEE
Coronary heart failure 4 (7.3%)
Left ventricular thrombus 3 (5.5%)
Hyperkalemia 1 (1.8%)
Ischemia 4 (7.3%)
Non revascularized left 1 (1.8%)
anterior descending
Perforation/pericardial tamponade 1 (1.8%)
Prolonged procedure 2 (3.6%)
Risk of ventricular fibrillation 1 (1.8%)
Severe aortic stenosis 1 (1.8%)
Ventricular fibrillation non inducible 2 (3.6%)
Unknown 1 (1.8%)
Table 4. Differences in outcomes between patients who underwent defibrillation threshold (DFT)
testing vs. those who did not at the time of ICD implantation.
No-DFT group (n = 55) DFT group (n = 57) P
Number of patients alive 38 (69.1%) 52 (91.2%) 0.004^
Recorded arrhythmias 0.037
NSVT 0 5 (8.8%)
Ventricular tachycardia 7 (12.7%) 13 (22.8%)
Ventricular fibrillation 5 (9.1%) 2 (3.1%)
None  43 (78.2%) 37 (64.9%)
Clinical shock efficacy 11 (91.7%) 16 (94.1%) 0.99^
Total shocks 51 54 0.57*
Total arrhythmic episodes treated 46 48 0.19*
*p based on t-test, ^Fischer exact test
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Discussion
Several recent studies have looked at the need
for routine DFT testing at the time if ICD system
implantation [15–17]. In addition to increasing costs,
induction and termination of VF can be associated
with increased morbidity [19–21]. Multiple VF in-
ductions at the time of ICD implantation with high-
er defibrillation energy requirements has been as-
sociated with higher mortality rates during follow-
up [15]. While Brunn et al. [16] reported a 0.4% fail-
ure of ICD during routine tests, Russo et al. [18]
reported an inadequate safety margin in 6% of pa-
tients undergoing ICD implantation.
In this study, we compared the clinical out-
comes in patients who underwent routine DFT
implant testing with those patients in whom DFT
testing was precluded by their other clinical comor-
bidities. In our study, there was a survival benefit
for patients who underwent DFT testing. This is
perhaps not surprising given the No-DFT group
likely represented a sicker group of patients who
were believed to be at increased risk for VF induc-
tion. However, multivariate analysis revealed sev-
eral variables including No-DFT testing as inde-
pendent predictor of mortality. In addition Kaplan-
-Meier curves showed a survival benefit even from
very early follow-up. There were more deaths at-
tributable to VF in the No-DFT group (3/17 deaths
17.6%). We were unable to obtain ICD intracardiac
electrograms after the deaths of these patients.
Thus, we do not know if these arrhythmic events
represented failed therapy versus exhaustion of
ICD therapy with no termination of the arrhythmia.
Our study findings are of significant interest be-
cause the need for routine DFT testing at the time
of ICD implant is being questioned.
While some studies have favored routine DFT
testing at the time of ICD implantation [17, 18],
others have questioned the utility in testing every
patient [16]. Untreated ventricular tachyarrhythmi-
as due to programming errors have been reported
and implicated as the cause of sudden cardiac death
in some patients [22]. It is certainly also possible
for leads to be misplaced or not inserted all the way
to the distal set screw leading to inappropriate or
ineffective shock therapy. It is for these reasons
that performing DFT testing at the time of ICD
implantation remains the standard of care.
While most patients tolerate VF induction and
termination, implant DFT testing can be associated
with negative clinical outcomes such as significant
Table 5. Cause specific mortality between pa-
tients who underwent defibrillation threshold
(DFT) testing vs. those who did not at the time of
ICD implantation.
Causes No-DFT group DFT group
(n = 17) (n = 5)
Acute myocardial 0 1 (20 %)
infarction
Aspiration pneumonia 0 1 (20%)
ESRD 1 (5.9%) 0
Refractory coronary 8 (47.1%) 1 (20%)
heart failure
Sepsis 3 (17.6%) 0
Ventricular fibrillation 3 (17.6%) 0
Unknown 2 (11.8%) 2 (40%)
P value based on c2 test based on double variables was 0.081
Figure 1. Kaplan-Meier survival analysis curves in pa-
tient who underwent defibrillation threshold (DFT) te-
sting and those who did not have DFT testing at the
time of ICD implantation.
Table 6. Cox regression analysis: Predictors of all cause mortality.
Variables Hazard ratio 95% confidence interval P
No defibrillation threshold 3.18 0.82–12.41 0.095
Male gender 0.47 0.18–1.27 0.136
NYHA 2.59 0.79–8.45 0.115
Coronary artery bypass grafting 0.64 0.21–1.96 0.43
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hemodynamic compromise [21]. Therefore, certain
patients who have other co-morbidities often do not
undergo DFT testing. When DFT testing is not
performed, first shock energy is usually pro-
grammed to maximal output. However, Russo et al.
[18] showed that use of high shock energy output
(≥ 35 J) alone did not allow for an adequate safety
margin in 3% of their study population. Further
device system modification to achieve adequate
DFT did not result in a mortality difference [18].
There are few studies that have looked at the
outcomes in patients who did not undergo DFT test-
ing at the time of ICD implantation. Thus, it is im-
possible to know what the long term clinical out-
comes would be if implant DFT testing was elimi-
nated all together. Pires et al. [23] found in their
retrospective analysis that patients who did not
undergo intraoperative defibrillation testing had
significantly higher overall mortality rates than
those who underwent either DFT or defibrillation
safety margin testing. However, the three groups
had comparable successes of ICD therapies against
spontaneous VT/VF and sudden-death-free survival
rates. The results of our study would corroborate
these findings. Strickberger et al. [14] point to the
fact in their review that eliminating DFT testing
may allow non electrophysiologists to implant defi-
brillators allowing for a greater number of patients
to be reached that may benefit from ICD therapy.
However our study results favors DFT testing or
at least safety margin testing should be done when
feasible. A much larger prospective randomized trial
would need to be conducted prior to making any
such conclusions.
Limitations of this study include non-randomi-
zation, smaller sample size and shorter duration of
follow up. We were also unable to determine the
cause of death in 13.7% of patients. It is possible
that a portion or all of these deaths were arrhyth-
mic deaths which could affect the results of this
study. Also, adjusting for severity of illness between
the two groups may be imperfect. This is especial-
ly true given the relatively smaller number of deaths
which limits the power of regression analysis to
detect the predictors of death. The mean differences
in age between the two groups, although statisti-
cally not significant should be noted. Also case con-
trol study design is inferior to randomized clinical
trial to prove causality. Ideally controls should be
matched with age, gender and co-morbidities and
our data has a higher percentage of co-morbidities
in the No-DFT group which could bias the results.
Conclusions
In summary, the overall mortality was higher
in the No-DFT group even after adjusting for other
clinical variables. There were more episodes of VF
and deaths attributable to VF in the No-DFT group.
These findings suggest that DFT testing should re-
main the standard of care until we have further data
from large randomized trials. However, ICD thera-
py should not be withheld in patients who meet ap-
propriate implant criteria simply of the basis of clin-
ical scenarios that preclude routine DFT testing.
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